Background: There are limited data to inform positioning of agents for treating
| INTRODUCTION
Anti-tumour necrosis factor-a (TNF) agents have traditionally been first-line biologic agents for the management of moderate-severe Crohn's disease refractory to conventional therapy (mesalazine [mesalamine], steroids, immunosuppressive agents). 1, 2 Approximately onethird of biologic-na€ ıve patients with Crohn's disease may not respond to induction therapy, and among those who respond, up to 45% will progressively lose response over time. 3, 4 Over In the absence of direct evidence from head-to-head trials, network meta-analysis can help assess comparative efficacy of several interventions and synthesise evidence across a network of randomised controlled trials (RCTs), especially if there is weak (or absent) direct evidence. 5 Such indirect comparisons of competing interventions, adjusted by a common control, such as placebo, can partially take account of prognostic characteristics of patients in different trials, and may inform patients, clinicians, policymakers and other stakeholders regarding the optimal use of these agents in clinical practice. Most network meta-analyses in patients with Crohn's disease have focused on comparative efficacy of different agents in a biologic-na€ ıve patient population, [6] [7] [8] and there is limited critical synthesis of data on the optimal positioning of these agents in the management of patients with prior exposure to anti-TNF agents. Moreover, with its recent approval, ustekinumab has not been included in these studies.
Hence, we conducted a systematic review with pairwise and network meta-analyses, comparing the relative efficacy and safety of anti-TNF agents (infliximab, adalimumab, certolizumab pegol), antiintegrin agents (vedolizumab) and anti-IL12/23 agents (ustekinumab), as first-and second-line agents in patients with moderate-severe
Crohn's disease. We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria for network meta-analysis to appraise the quality of the evidence. 9 
| ME TH ODS
This systematic review was performed using an a priori established protocol, and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for systematic reviews incorporating network meta-analyses for health care interventions. 10 We followed good research practices outlined in the International Society for Pharmacoeconomics and Outcomes Research report on interpreting indirect treatment comparisons and network meta-analysis for healthcare decision-making. 
| Search strategy, data abstraction and risk of bias assessment
We conducted a comprehensive search of multiple electronic databases through May 31, 2017, with no language restrictions. Details of the search strategy are shown in Appendix S1. Data on study-, participant-, disease-and treatment-related characteristics were abstracted onto a standardised form, by 2 investigators (SS and MF) independently and discrepancies were resolved by consensus, referring back to the original article, in consultation with a third reviewer (WJS).
Two study investigators, independently, rated the risk of bias of included studies using the criteria established by the Evidence-Based Gastroenterology Steering Group. 12 These include: (a) concealed random allocation; (b) blinding of patients and caregivers; (c) equal use of co-interventions for the treatment and placebo groups; (d) complete follow-up of study patients; and (e) use of an intention-to-treat analysis.
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| Outcomes
For trials of induction therapy, the primary efficacy outcome was induction of clinical remission (CDAI <150); secondary efficacy outcome was clinical response (CR-100, defined as achieving a reduction of ≥100 points in CDAI from baseline). Due to limitations of short-term trials in evaluating treatment safety, it was not included as an outcome for induction therapy. For trials of maintenance therapy, the efficacy outcome was maintenance of clinical remission (CDAI <150), and safety outcomes were serious adverse events (study-defined) and infections, which were analysed quantitatively.
We also reviewed all trials reporting endoscopic remission and patient-reported outcome measures as important end points, with the intention to perform meta-analysis if adequate data was available.
When data for multiple doses of the same medication was available, then only data for approved dose and administration was considered. The timing of outcome assessment with induction trials was up to 14 weeks; when outcomes at multiple time points were reported, we used outcomes at week 8 or 6. For maintenance trials, outcomes were assessed at last point of follow-up, usually week 52.
The denominator used in all trials was based on intention-to-treat analysis, and all dropouts were assumed to be treatment failures for the primary outcome of clinical remission. For safety outcome, lastobservation-carried-forward imputation was used.
| Data synthesis and statistical analysis
Pooled odds ratios (OR) and 95% confidence intervals (CI), were estimated using the Mantel-Haenszel fixed-effects model (in the absence of conceptual heterogeneity and if <5 studies), with sensitivity analysis using the DerSimonian-Liard random-effects model. [13] [14] [15] We assessed statistical heterogeneity using the I 2 statistic, with values over 50% suggesting substantial heterogeneity. Publication bias was assessed by evaluating small-study effects by examining funnel plot asymmetry. 16 Direct comparisons were performed using RevMan v53 (Cochrane Collaboration, Copenhagen, Denmark). Network meta-analysis was conducted using a multivariate, consistency model, random-effects meta-regression as described by Ian White, using STATA v.15.0 (College Station, TX, USA). 17 This frequentist approach provides a point estimate from the network along with 95% CI from the frequency distribution of the estimate.
We estimated the relative ranking of agents for induction of clinical remission as their surface under the cumulative ranking (SUCRA), which represents the percentage of efficacy or safety achieved by an agent compared to an imaginary agent that is always the best without uncertainty (ie SUCRA = 100%). 18 Higher SUCRA scores correspond to higher ranking for induction of clinical remission and/ or mucosal healing, and higher ranking for safety (ie lowest risk of serious adverse events and infections).
Finally, we generated estimates of absolute event rates (or absolute risk) using the GRADEpro version 3.6 (McMaster University, 2014) (Appendix S1). 19 
| Confidence in estimates
We followed the GRADE approach to appraise the confidence in estimates derived from network meta-analysis of efficacy outcomes. 9 In this approach, direct evidence from RCTs starts at high confidence and can be rated down based on risk of bias, indirectness, imprecision, inconsistency (or heterogeneity) and/or publication bias, to levels of moderate, low and very low confidence. The rating of indirect estimates starts at the lowest rating of the 2 pairwise estimates that contribute as first-order loops to the indirect estimate but can be rated down further for imprecision or intransitivity (dissimilarity between studies in terms of clinical or methodological characteristics). If direct and indirect estimates were similar (ie coherent), then the higher of their rating can be assigned to the network meta-analysis estimates.
| RESULTS
From a total 1866 unique studies identified using our search strategy, we included 8 RCTs of first-line agents (in biologic-na€ ıve patients), [20] [21] [22] [23] [24] [25] [26] [27] 6 RCTs of second-line agents (in patients with prior anti-TNF exposure), [23] [24] [25] [27] [28] [29] and 9 RCTs of maintenance therapy, [23] [24] [25] [29] [30] [31] [32] [33] [34] in patients with moderate-severe Crohn's disease.
The schematic diagram of study selection is shown in Figure S1 and available direct comparisons and network of trials are shown in Tables 1 and 2 
Induction of clinical remission
On direct meta-analysis, all agents, except certolizumab pegol, were superior to placebo for induction of clinical remission, and effect size was strongest for infliximab (OR, 6.35) and adalimumab (OR, 3.80) ( Figure 3 ). On network meta-analysis, compared to placebo, there was moderate confidence in estimates supporting the use of infliximab, adalimumab, certolizumab pegol, vedolizumab and ustekinumab for induction of clinical remission in biologic-na€ ıve patients (evidence rated down due to imprecision due to the small number of events and not meeting optimal information size) ( Table 3 and Table S3 respectively, may be expected to achieve remission with induction therapy (Table S3) .
Induction of clinical response
Overall findings on direct meta-analysis ( Figure 3 ) and network meta-analysis (Table 3) for clinical response outcome were comparable to primary findings for clinical remission outcome.
| Second-line biologic therapy for moderatesevere Crohn's disease
Overall, 6 RCTs including 1606 patients with moderate-severe CD with prior exposure to anti-TNF agents were identified. [23] [24] [25] [27] [28] [29] These included 3 trials conducted exclusively in patients with prior exposure to anti-TNF agents (1 trial of adalimumab, 28 (evidence rated down due to imprecision due to the small number of events and not meeting optimal information size) ( Table 4 and   Table S3 ). In contrast, despite a similar summary estimate, only lowquality evidence supported the use of adalimumab (OR, 3.57; 95% CI, 1.66-7.65), with evidence being rated down for indirectness due to selective inclusion of patients with prior response or intolerance to anti-TNF agents, and for imprecision due to a small number of events. There was low confidence in estimates supporting a small effect size of vedolizumab (OR, 1.53; 95% CI, 0.77-3.06) for induction of clinical remission over placebo, due to very serious and vedolizumab-treated patients would achieve induction of remission (Table S3 ).
| Induction of clinical response
Overall findings on direct meta-analysis ( Figure S4 ) and network meta-analysis ( 
| Efficacy
On direct meta-analysis, all agents were superior to placebo for induction of clinical remission ( Figure 5 ). Results were stable on exclusion of a 22-week trial of maintenance therapy with ustekinumab (data not shown). On network meta-analysis, compared to placebo, moderate confidence in estimates supported a large effect size for adalimumab, and a moderate effect size of infliximab, certolizumab pegol, ustekinumab and vedolizumab for maintenance of clinical remission in patients who had responded to induction therapy with the same medication (evidence rated down due to imprecision due to low event rate not meeting optimal information size) (Table 5 and Table S3 ). (Table S3) . 
| Safety

| Publication bias
Evaluation of funnel plots did not reveal evidence of small-study effects; however, the number of studies for each comparison was small; thus, we cannot reliably detect publication bias.
| DISCUSSION
In this systematic review and network meta-analysis combining direct and indirect evidence from 18 trials in biologic-na€ ıve and biologic-exposed patients with moderate-severe Crohn's disease, we made several key observations. First, in biologic-na€ ıve patients, anti-TNF agents, infliximab and adalimumab, are ranked highest for inducing clinical remission and response. On comparison of active interventions, standard-dose infliximab is probably superior to certolizumab pegol, and may be superior to ustekinumab and vedolizumab. Infliximab and adalimumab are also superior to other agents for maintenance of remission. Second, in patients with prior exposure to critical appraisal of quality of evidence, may help inform optimal selection of first-and second-line biologic agents in the management of moderate-severe Crohn's disease, and facilitate shared decision.
Our findings on comparative efficacy of first-line biologic therapy in patients with moderate-severe Crohn's disease builds on previous network meta-analyses. [6] [7] [8] In this study, by updating analyses with inclusion of ustekinumab, adding the GRADE framework and assessment of absolute effect size, and performing a thorough quantitative and qualitative assessment of safety of different therapies, we have been able to contextualise our confidence in the summary estimates for different comparisons, and more thoroughly inform positioning of different first-line agents. Our findings suggest that efficacy of ustekinumab is not superior to infliximab and adalimumab, and is comparable to vedolizumab in biologic-na€ ıve patients. Standard-dose certolizumab pegol was ranked inferior to all other agents, and had significantly lower efficacy than infliximab and ustekinumab for induction of clinical remission. This may be related to potential inadequacy of dose-finding studies to fully explore dose-response for certolizumab pegol. We acknowledge that there is paucity of headto-head trials to truly inform comparative efficacy and safety, and several indirect comparisons for active interventions resulted in lowto very low-quality evidence. Moreover, there is low confidence in estimates supporting a large effect size for infliximab due to lack of appropriate induction trials of infliximab.
Studying the comparative efficacy of different agents as secondline therapy in patients with prior anti-TNF exposure is novel in this study. This is increasingly relevant given high rates of primary nonresponse or secondary loss of response to initial biologic therapy, and is an often-faced clinical scenario for which there is limited guidance.
In the absence of head-to-head trials or prospective observational studies, our findings provide the first insights on comparative efficacy of second-line agent from an evidence-based medicine stand- 
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Odds Ratio Odds Ratio F I G U R E 3 Efficacy of pharmacological agents in biologic-na€ ıve patients with moderate-severe Crohn's disease for induction of clinical remission GAIN trial of adalimumab selectively included only patients with prior response followed by secondary loss of response or intolerance to infliximab, excluding patients with primary nonresponse. 33 In a meta-analysis of observational studies, Gisbert and colleagues observed differences in response to second line anti-TNF depending on reason for discontinuation of first anti-TNF agent-while 61% patients who were switched to adalimumab due to intolerance to infliximab achieved remission, only 45% of patients with secondary loss of response, and 31% of patients with primary nonresponse to infliximab were able to achieve remission with second line anti-TNF agent. 35 In a recent meta-analysis, we demonstrated that even response to non-TNF-biologics is inferior in patients who have had a primary nonresponse to prior anti-TNF agents, as compared to those who had prior secondary loss of response or intolerance. 36 Findings from these indirect comparisons need to be interpreted with caution since these trials did not always mirror clinical practice. For example, current trials did not utilise therapeutic drug monitoring to understand the plausible mechanism of failure of initial biologic intervention. Given potential differences in efficacy of second-line interventions depending on underlying reason for discontinuation of prior anti-TNF therapy (primary nonresponse vs secondary loss of response vs intolerance), such information may be useful in making clinical treatment decisions in conjunction with findings from our analyses. 35, 36 In these analyses, data on how many prior anti-TNF agents to which a patient had been exposed was not consistently reported. It is conceivable (and likely) that since anti-TNF agents We accounted for this observation in the GRADE schema by rating down comparisons of active interventions for intransitivity, and for imprecision, resulting in low-or very low-quality of evidence.
Besides inherent limitations of individual trials, there are limitations to our analyses. There were no head-to-head trials, and all comparative efficacy and safety analyses were based on indirect T A B L E 4 Comparative efficacy of biologic agents for induction of clinical remission and clinical response in patients with moderate-severe Crohn's disease with prior exposure to anti-TNF agents, network meta-analysis. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment. Bold numbers with darker background are statistically significant. For induction of clinical remission, odds ratio >1 favours row-defining treatment. While corticosteroid-free remission may be a more relevant clinical endpoint, this was inconsistently reported in included trials.
T A B L E 5 Comparative efficacy and safety of biologic agents for maintenance of clinical remission and any infections in patients with moderate-severe Crohn's disease with response to induction therapy, using network meta-analysis. 
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Additional supporting information will be found online in the Supporting Information section at the end of the article.
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